Analysts Anticipate Arcadia Biosciences, Inc. (NASDAQ:RKDA) Will Announce Earnings of -$0.31 Per Share

Share on StockTwits

Brokerages expect Arcadia Biosciences, Inc. (NASDAQ:RKDA) to report earnings per share of ($0.31) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Arcadia Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.22). Arcadia Biosciences reported earnings per share of ($0.45) during the same quarter last year, which indicates a positive year-over-year growth rate of 31.1%. The company is expected to issue its next earnings results on Wednesday, May 12th.

According to Zacks, analysts expect that Arcadia Biosciences will report full year earnings of ($0.91) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.78). For the next financial year, analysts forecast that the business will post earnings of ($0.57) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Arcadia Biosciences.

Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings data on Monday, March 29th. The basic materials company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $1.29. The firm had revenue of $7.13 million during the quarter, compared to analyst estimates of $1.26 million. Arcadia Biosciences had a negative return on equity of 177.69% and a negative net margin of 1,499.85%.

Separately, HC Wainwright cut their target price on Arcadia Biosciences from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 9th.

Several institutional investors have recently added to or reduced their stakes in the stock. Moloney Securities Asset Management LLC purchased a new stake in shares of Arcadia Biosciences during the 1st quarter valued at about $198,000. GSA Capital Partners LLP raised its stake in Arcadia Biosciences by 26.8% during the 4th quarter. GSA Capital Partners LLP now owns 128,039 shares of the basic materials company’s stock valued at $324,000 after buying an additional 27,084 shares during the last quarter. Wells Fargo & Company MN raised its stake in Arcadia Biosciences by 60.5% during the 4th quarter. Wells Fargo & Company MN now owns 31,057 shares of the basic materials company’s stock valued at $78,000 after buying an additional 11,704 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in shares of Arcadia Biosciences by 17.6% during the 4th quarter. LPL Financial LLC now owns 26,750 shares of the basic materials company’s stock valued at $68,000 after buying an additional 4,000 shares during the period. 8.03% of the stock is currently owned by institutional investors.

NASDAQ RKDA traded up $0.01 on Tuesday, hitting $2.59. The company’s stock had a trading volume of 795,097 shares, compared to its average volume of 2,608,847. The company’s 50-day simple moving average is $2.67 and its 200 day simple moving average is $2.98. The firm has a market cap of $55.26 million, a P/E ratio of -1.25 and a beta of -0.62. The company has a current ratio of 2.52, a quick ratio of 1.40 and a debt-to-equity ratio of 0.21. Arcadia Biosciences has a 52-week low of $2.26 and a 52-week high of $6.40.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, a consumer-driven agricultural technology company, engages in developing various crop productivity traits primarily in hemp, wheat, and soybean. The company's crop productivity traits are designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications.

Recommended Story: 52-Week High/Low

Get a free copy of the Zacks research report on Arcadia Biosciences (RKDA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with's FREE daily email newsletter.